Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC

This publication has 25 references indexed in Scilit:

• Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
  Radiotherapy and Oncology, 2004
• Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab
  Journal of Clinical Oncology, 2004
• Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma
  Radiotherapy and Oncology, 2004
• Review of epidermal growth factor receptor biology
  International Journal of Radiation Oncology*Biology*Physics, 2004
• EGFRvIII-mediated radioresistance through a strong cytoprotective response
  Oncogene, 2003
• Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse.
  International Journal of Radiation Biology, 2003
• Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
  International Journal of Radiation Oncology*Biology*Physics, 2002
• Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice
  Radiotherapy and Oncology, 1994
• Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice
  JNCI Journal of the National Cancer Institute, 1988